Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Ovarian Cancer

In a phase 2 study of women with recurrent platinum-sensitive ovarian cancer, safety and efficacy end points favored the combination of niraparib and bevacizumab over niraparib monotherapy.
New study findings represent a significant advance for women with BRCA-related relapsed ovarian cancer responding to platinum-based chemotherapy.
In the PRIMA study, patients with recurrent ovarian cancer receiving maintenance therapy with an individualized dose of niraparib had similar efficacy compared with placebo as patients receiving a fixed dose of niraparib while experiencing half as many thrombocytopenic events.
In a pooled analysis of 2 randomized trials of rucaparib for the treatment of patients with recurrent high-grade ovarian cancer, deleterious BRCA mutations were identified in 71% of patients with responses lasting at least 1 year but in only 52% of short-term responders.
In a study of 76 English-speaking women with newly diagnosed ovarian cancer who underwent genetic testing, those found to have a pathogenic mutation did not report increased levels of stress, anxiety, or depression compared with pre-genetic testing. Those testing negative for mutations saw their posttest anxiety levels decline.
Results from the phase 3 ARIEL3 clinical trial showed that maintenance therapy with rucaparib leads to significantly improved progression-free survival in patients with advanced ovarian cancer and non-BRCA homologous recombinant repair gene mutations.
At the 12-month landmark analysis of the single-arm phase 2 OVARIO clinical trial, 75% of patients in the overall population of patients with newly diagnosed stage IIIB-IV ovarian cancer remained progression-free.
Data from the phase 3 PAOLO-1 clinical trial showed that progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy.
The approval of 3 PARP inhibitors has made it feasible to personalize therapy for patients with ovarian cancer based on their mutation status as well as other factors, including the treatment setting.
The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients.
Page 1 of 5
Results 1 - 10 of 42